...
首页> 外文期刊>The Journal of Infectious Diseases >Clinical outcomes among persons with pulmonary tuberculosis caused by Mycobacterium tuberculosis isolates with phenotypic heterogeneity in results of drug-susceptibility tests
【24h】

Clinical outcomes among persons with pulmonary tuberculosis caused by Mycobacterium tuberculosis isolates with phenotypic heterogeneity in results of drug-susceptibility tests

机译:在药物敏感性试验结果中,由表型异质性分离的结核分枝杆菌引起的肺结核患者的临床结局

获取原文
获取原文并翻译 | 示例
           

摘要

Background. Patients with multidrug-resistant (MDR) tuberculosis may have phenotypic heterogeneity in results of drug-susceptibility tests (DSTs). However, the impact of this on clinical outcomes among patients treated for MDR tuberculosis is unknown.Methods. Phenotypic DST heterogeneity was defined as presence of at least 1 Mycobacterium tuberculosis isolate susceptible to rifampicin and isoniazid recovered <3 months after MDR tuberculosis treatment initiation from a patient with previous documented tuberculosis due to M. tuberculosis resistant to at least rifampicin and isoniazid. The primary outcome was defined as good (ie, cure or treatment completion) or poor (ie, treatment failure, treatment default, or death). A secondary outcome was time to culture conversion. Cox proportional hazard models were used to determine the association between phenotypic DST heterogeneity and outcomes. Results. Phenotypic DST heterogeneity was identified in 33 of 475 patients (7%) with MDR tuberculosis. Poor outcome occurred in 126 patients (28%). Overall, patients with MDR tuberculosis who had phenotypic DST heterogeneity were at greater risk of poor outcome than those with MDR tuberculosis but no phenotypic DST heterogeneity (adjusted hazard ratio [aHR], 2.1; 95% confidence interval [CI], 1.2-3.6). Among HIV-infected patients with MDR tuberculosis, the adjusted hazard for a poor outcome for those with phenotypic DST heterogeneity was 2.4 (95% CI, 1.3-4.2) times that for those without phenotypic DST heterogeneity, whereas among HIV-negative patients with MDR tuberculosis, the adjusted hazard for those with phenotypic DST heterogeneity was 1.5 (95% CI,. 5-4.3) times that for those without phenotypic DST heterogeneity. HIV-infected patients with MDR tuberculosis with phenotypic DST heterogeneity also had a longer time to culture conversion than with HIV-infected patients with MDR tuberculosis without phenotypic DST heterogeneity (aHR, 2.9; 95% CI, 1.4-6.0).Conclusions. Phenotypic DST heterogeneity among persons with HIV infection who are being treated for MDR tuberculosis is associated with poor outcomes and longer times to culture conversion.
机译:背景。在药物敏感性测试(DST)的结果中,患有多重耐药性(MDR)结核病的患者可能具有表型异质性。然而,这对接受MDR结核治疗的患者的临床结果的影响尚不清楚。表型DST异质性定义为存在至少一种对利福平敏感的结核分枝杆菌分离株,在MDR结核治疗开始后3个月内从患有结核分枝杆菌的至少一名对利福平和异烟肼耐药的结核病患者中恢复了异烟肼。主要结果定义为好(即治愈或治疗完成)或差(即治疗失败,治疗失误或死亡)。次要结果是进行文化转化的时间。使用Cox比例风险模型确定表型DST异质性与结果之间的关联。结果。表型DST异质性在475例耐多药结核病患者中有33例(7%)被发现。 126例患者(28%)的预后不良。总体而言,具有表型DST异质性的MDR结核患者比具有MDR结核但无表型DST异质性的患者更有可能出现较差的结局风险(调整后的危险比[aHR]为2.1; 95%的置信区间[CI]为1.2-3.6) 。在具有表型DST异质性的HIV感染的MDR肺结核患者中,校正后的不良后果风险是没有表型DST异质性的患者的2.4倍(95%CI,1.3-4.2),而在具有HIV阴性的MDR结核病患者中结核病,具有表型DST异质性的人的调整后危害是没有表型DST异质性的人的1.5倍(95%CI,5-4.3)倍。与表型DST异质性异质性的MDR结核病的HIV感染患者相比,没有表型DST异质性异质性的MDR结核病患者(aHR,2.9; 95%CI,1.4-6.0)有更长的培养转化时间。在接受耐多药结核病治疗的艾滋病毒感染者中,表型DST异质性与不良结果和更长的培养转化时间有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号